# NATIENS: Optimal Management and Mechanisms of SJS/TEN

> **NCT02987257** · PHASE3 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Stevens-Johnson Syndrome
- Toxic Epidermal Necrolyses

## Interventions

- **DRUG:** Harmonized supportive care
- **DRUG:** Etanercept 50 mg sc day 1 and day 4

## Key facts

- **NCT ID:** NCT02987257
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987257, "NATIENS: Optimal Management and Mechanisms of SJS/TEN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02987257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*